Annora Pharma is a finished-dose manufacturer based in India. It appears in 85 regulatory filings across 11 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, JFDA (JO) and INVIMA (CO). Its GMP standing is certified by ANVISA (Brazil), EAEU_EEC and NAFDAC (NG), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 28 March 2025 as VAI. Customs aggregates show $169.8M of exports covering 2,741 molecules to 23 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| TELANGANA, India | Not on file |
| Hyderabad, India | Not on file |
| Sangareddy, India | 3013944676 |
| TELANGANA STATE, Nigeria | Not on file |
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 21 | 1 |
| JFDA (JO) | 17 | None |
| INVIMA (CO) | 16 | None |
| ARCSA (EC) | 9 | None |
| NCELS (KZ) | 6 | 1 |
| COFEPRIS (MX) | 5 | None |
| ANVISA (Brazil) | None | 4 |
| EAEU_EEC | None | 3 |
| NAFDAC (NG) | None | 2 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $169.8M | 23 |
| 2024 | Not reported | $166.4M | 14 |
| 2023 | Not reported | $149.3M | 7 |
| 2022 | Not reported | $97.5M | 10 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Annora Pharma comes back tiered against every other supplier able to file there.
Start for free